The US Food and Drug Administration has cleared the first China-developed cancer drug similar to Merck & Co.’s blockbuster therapy Keytruda, making it a rare success among Chinese biotechnology firms seeking to break into the world’s most lucrative market.
The FDA granted approval for Loqtorzi to Shanghai Junshi Biosciences Ltd and its US partner Coherus BioSciences Inc. to treat nasaopharyngeal cancer, the Chinese company said in a statement on Friday.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.